Lumos Pharma is focused on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. Lumos Pharma is led by an experienced management team with longstanding experience in the rare disease space. Lu...Show all
Company (Alive / Active)
4200 Marathon Blvd.
Texas, United States
|Investor||Investor Type||Location||Participating Rounds|
|San Francisco, California, United States||IPO / Went public||Audentes is a biotechnology company committed to the development and commercialization of treatments for people with serious, rare diseases through the application of AAV gene therapy technology. The company has three products in development, AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT002 for the treatment of Pompe disease, and AT003 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).||Login to see details|